BCL2L1 and ovarian cancer: In ovarian carcinoma, BCL-XL and MCL1 are gateway proteins guarding together against apoptosis and their concomitant inhibition is sufficient to elicit apoptosis in chemoresistant ovarian cancer cell lines.7, 8, 9 On the basis of this assumption, the development of therapeutic strategies aiming at targeting concomitantly these two proteins could constitute an interesting alternative treatment of ovarian carcinoma.